Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

Novo Nordisk continues to deliver strong revenue, profit growth, and high economic profitability. Read why I rate NVO stock a ...

Shares of Novo Nordisk Inc. (NYSE: NVO) are trading lower Tuesday after a new study raised concerns about a potential link ...

Novo Nordisk's early lead in weight-loss drugs fades as Eli Lilly surges ahead with more effective therapies and faster ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.

Novo Nordisk’s weight-loss drug Wegovy has been surpassed in weekly U.S. prescriptions by Eli Lilly’s Zepbound, and now the ...

“While the term ‘Ozempic Butt’ may be new, the concept of being left with sagging skin after rapidly losing a large amount of ...

The Delhi High Court declined to stop Dr. Reddy’s from manufacturing Novo Nordisk’s drug, but will continue to hear the ...

The undertaking to Delhi HC follows a patent infringement plea filed by the Danish drugmaker against Dr Reddy’s Laboratories ...

Doctors have warned users of medicines such as Ozempic Wegovy and Mounjaro about an irreversible potential side effect ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.